Skip to Content

Remifentanil Injection

Last Updated: March 14, 2019
Status: Current

Products Affected - Description
    • Ultiva lyophilized powder for injection, Mylan Institutional, 1 mg, vial, 10 count, NDC 67457-0198-03
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
Reason for the Shortage
    • Mylan Institutional did not provide a reason for the shortage.
    • Fresnius Kabi launched generic remifentanil in January 2018.
Available Products
    • Ultiva lyophilized powder for injection, Mylan Institutional, 2 mg, vial, 10 count, NDC 67457-0198-05
    • Ultiva lyophilized powder for injection, Mylan Institutional, 5 mg, vial, 10 count, NDC 67457-0198-10

Estimated Resupply Dates

    • Mylan Institutional has Ultiva 1 mg vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has remifentanil 2 mg and 5 mg vials on back order and the company cannot estimate a release date. The 1 mg vials are on back order and the company estimates a release date of early-April 2019.

Updated

Updated March 14, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 2, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide